Breast cancer treatment: a review
AG Waks, EP Winer - Jama, 2019 - jamanetwork.com
Importance Breast cancer will be diagnosed in 12% of women in the United States over the
course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed …
course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed …
[HTML][HTML] Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
…, A Saltzman, NM Oliver, L Marini, AG Waks… - Nature …, 2017 - nature.com
Whole-exome sequencing of cell-free DNA (cfDNA) could enable comprehensive profiling
of tumors from blood but the genome-wide concordance between cfDNA and tumor biopsies …
of tumors from blood but the genome-wide concordance between cfDNA and tumor biopsies …
Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with …
…, VG Abramson, CL Arteaga, LM Spring, AG Waks… - Cancer discovery, 2021 - AACR
HER2-targeted therapies improve cure rates in HER2-positive breast cancer, suggesting
chemotherapy can be avoided in a subset of patients. We show that HER2 heterogeneity, …
chemotherapy can be avoided in a subset of patients. We show that HER2 heterogeneity, …
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies
Seventy percent of breast cancers express the estrogen receptor (ER), and agents that target
the ER are the mainstay of treatment. However, virtually all people with ER + breast cancer …
the ER are the mainstay of treatment. However, virtually all people with ER + breast cancer …
Timeliness in breast cancer treatment—the sooner, the better
AG Waks, TA King, EP Winer - JAMA oncology, 2016 - jamanetwork.com
Defining the impact of delays in breast cancer care is a difficult task. Although the question—“when
should I undergo treatment?”—is simple, necessary, and asked by patients every day…
should I undergo treatment?”—is simple, necessary, and asked by patients every day…
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor–positive metastatic breast …
We identified eight distinct mechanisms of resistance to CDK4/6i present in 66% of resistant
tumors profiled. Most of these have a therapeutic strategy to overcome or prevent resistance …
tumors profiled. Most of these have a therapeutic strategy to overcome or prevent resistance …
[HTML][HTML] The immunology of hormone receptor positive breast cancer
…, T Vallius, J Davis, YX Cui, J Agudo, AG Waks… - Frontiers in …, 2021 - frontiersin.org
Immune checkpoint blockade (ICB) has revolutionized the treatment of cancer patients. The
main focus of ICB has been on reinvigorating the adaptive immune response, namely, …
main focus of ICB has been on reinvigorating the adaptive immune response, namely, …
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
Background We aimed to report on long-term outcomes of patients with small, node-negative,
HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab and to …
HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab and to …
[HTML][HTML] Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
AG Waks, O Cohen, B Kochupurakkal, D Kim… - Annals of …, 2020 - Elsevier
Background Little is known about mechanisms of resistance to poly(adenosine diphosphate-ribose)
polymerase inhibitors (PARPi) and platinum chemotherapy in patients with …
polymerase inhibitors (PARPi) and platinum chemotherapy in patients with …
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
…, MS Cuoco, P Exman, SA Wander, AG Waks… - Clinical Cancer …, 2020 - AACR
Purpose: To identify clinically relevant mechanisms of resistance to ER-directed therapies in
ER + breast cancer. Experimental Design: We conducted a genome-scale functional screen …
ER + breast cancer. Experimental Design: We conducted a genome-scale functional screen …